We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New AI Tool Classifies Brain Tumors More Quickly and Accurately

By LabMedica International staff writers
Posted on 20 May 2024
Print article
Image: The new AI tool can help beat brain tumors (Photo courtesy of Crystal Light/Shutterstock)
Image: The new AI tool can help beat brain tumors (Photo courtesy of Crystal Light/Shutterstock)

Precision in diagnosing and categorizing tumors is essential for delivering effective treatment to patients. Currently, the gold standard for identifying various types of brain tumors involves DNA methylation-based profiling. DNA methylation functions as a regulatory mechanism to control gene activity, essentially turning genes on or off. However, the time required for such testing can be a significant hindrance, often taking several weeks—a delay that can be critical when patients need prompt decisions regarding their treatment. Additionally, these tests are not widely available in most hospitals around the world. Now, a new artificial intelligence (AI) tool has been developed to classify brain tumors more quickly and accurately.

Researchers at The Australian National University (ANU, Canberra, Australia) have created DEPLOY. This new method predicts DNA methylation patterns to classify brain tumors into 10 major subtypes. DEPLOY utilizes histopathology images, which are microscopic images of patient tissue samples. The model was trained and validated on extensive datasets comprising around 4,000 patients from the US and Europe. DEPLOY demonstrated remarkable accuracy, achieving a rate of 95%. Additionally, in a subset of 309 samples that were particularly challenging to classify, DEPLOY provided diagnoses that were more clinically relevant than those initially given by pathologists. The researchers anticipate that DEPLOY could also be adapted for classifying other types of cancer in the future.

“This shows the potential future role of DEPLOY as a complementary tool, adding to a pathologist’s initial diagnosis, or even prompting re-evaluation in the case of disparities,” said Dr. Danh-Tai Hoang.

Related Links:
ANU


Print article

Channels

Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more

Molecular Diagnostics

view channel
Image: The blood test uses AI to predict Parkinson’s seven years before onset of symptoms (Photo courtesy of Kateryna Kon/Shutterstock)

AI-Powered Blood Test Predicts Parkinson's Seven Years before Symptoms Appear

Parkinson’s disease is currently the fastest-growing neurodegenerative disorder worldwide, affecting nearly 10 million people globally. It is a progressive disease caused by the deterioration and death... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Industry

view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.